Sharing of Clinical Trial Data and Samples: The Cancer Patient Perspective

被引:8
作者
Broes, Stefanie [1 ,2 ]
Verbaanderd, Ciska [1 ,3 ]
Casteels, Minne [1 ]
Lacombe, Denis [2 ]
Huys, Isabelle [1 ]
机构
[1] Katholieke Univ Leuven, Clin Pharmacol & Pharmacotherapy, Dept Pharmaceut & Pharmacol Sci, Leuven, Belgium
[2] European Org Res Treatment Canc, Brussels, Belgium
[3] Anticanc Fund, Strombeek Bever, Belgium
关键词
data sharing; sample sharing; patient perspective; ethical and legal implications; neoplasms; e-consent; ACCESS;
D O I
10.3389/fmed.2020.00033
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Today, many initiatives and papers are devoted to clinical trial data (and to a lesser extent sample) sharing. Journal editors, pharmaceutical companies, funding agencies, governmental organizations, regulators, and clinical investigators have been debating the legal, ethical, and social implications of clinical data and sample sharing for several years. However, only little research has been conducted to unveil the patient perspective. Aim: To substantiate the current debate, we aimed to explore the attitudes of patients toward the re-use of clinical trial samples and data and to determine how they would prefer to be involved in this process. Materials and Methods: Sixteen in-depth interviews were conducted with cancer patients currently participating in a clinical trial. Results: This study indicates a general willingness of cancer patients participating in a clinical trial to allow re-use of their clinical trial data and/or samples by the original research team, and a generally open approach to share data and/or samples with other research teams, but some would like to be informed in this case. Despite divergent opinions about how patients prefer to be engaged, ranging from passive donors up to those explicitly wanting more control, participants expressed positive opinions toward technical solutions that allow indicating their preferences. Conclusion: Patients were open to sharing and re-use of data and samples to advance medical research but opinions varied on the level of patient involvement and the need for re-consent. A stratified approach for consent that allows individualization of data and sample sharing preferences may be useful, yet the implementation of such an approach warrants further research.
引用
收藏
页数:8
相关论文
共 36 条
  • [1] [Anonymous], 2006, PERSONAL DATA PUBLIC
  • [2] Transparency and the European Medicines Agency - Sharing of Clinical Trial Data
    Bonini, Sergio
    Eichler, Hans-Georg
    Wathion, Noel
    Rasi, Guido
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (26) : 2452 - 2455
  • [3] Broes S, 2017, J CANCER POLICY, V13, P65, DOI 10.1016/j.jcpo.2017.07.006
  • [4] Toward a Tiered Model to share clinical Trial Data and samples in Precision Oncology
    Broes, Stefanie
    Lacombe, Denis
    Verlinden, Michiel
    Huys, Isabelle
    [J]. FRONTIERS IN MEDICINE, 2018, 5
  • [5] The social licence for research: why care.data ran into trouble
    Carter, Pam
    Laurie, Graeme T.
    Dixon-Woods, Mary
    [J]. JOURNAL OF MEDICAL ETHICS, 2015, 41 (05) : 404 - 409
  • [6] Committee on Strategies for Responsible Sharing of Clinical Trial Data
  • [7] Board on Health Sciences Policy
  • [8] Institute of Medicine, 2015, SHAR CLIN TRIAL DAT, P793, DOI [10.1001/jama.2015.292, DOI 10.1001/JAMA.2015.292]
  • [9] Share and protect our health data: an evidence based approach to rare disease patients' perspectives on data sharing and data protection - quantitative survey and recommendations
    Courbier, Sandra
    Dimond, Rebecca
    Bros-Facer, Virginie
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2019, 14 (1)
  • [10] De Boeck A, 2016, MORGEN